JP7569443B2 - テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法 - Google Patents

テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法 Download PDF

Info

Publication number
JP7569443B2
JP7569443B2 JP2023504008A JP2023504008A JP7569443B2 JP 7569443 B2 JP7569443 B2 JP 7569443B2 JP 2023504008 A JP2023504008 A JP 2023504008A JP 2023504008 A JP2023504008 A JP 2023504008A JP 7569443 B2 JP7569443 B2 JP 7569443B2
Authority
JP
Japan
Prior art keywords
butyl
butoxy
propyl
alkyl
propoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023504008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534983A (ja
JP2023534983A5 (cg-RX-API-DMAC7.html
Inventor
ザイファン レン
シュエフェン サン
ジンジェ ジョウ
キン シュ
Original Assignee
エコジーン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エコジーン インコーポレイテッド filed Critical エコジーン インコーポレイテッド
Publication of JP2023534983A publication Critical patent/JP2023534983A/ja
Publication of JP2023534983A5 publication Critical patent/JP2023534983A5/ja
Priority to JP2024174734A priority Critical patent/JP7795064B2/ja
Application granted granted Critical
Publication of JP7569443B2 publication Critical patent/JP7569443B2/ja
Priority to JP2025207454A priority patent/JP2026035735A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023504008A 2020-07-20 2021-07-20 テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法 Active JP7569443B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024174734A JP7795064B2 (ja) 2020-07-20 2024-10-04 テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法
JP2025207454A JP2026035735A (ja) 2020-07-20 2025-11-28 テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/102955 2020-07-20
CN2020102955 2020-07-20
CNPCT/CN2021/070120 2021-01-04
CN2021070120 2021-01-04
PCT/CN2021/107216 WO2022017338A1 (en) 2020-07-20 2021-07-20 Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024174734A Division JP7795064B2 (ja) 2020-07-20 2024-10-04 テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2023534983A JP2023534983A (ja) 2023-08-15
JP2023534983A5 JP2023534983A5 (cg-RX-API-DMAC7.html) 2024-07-29
JP7569443B2 true JP7569443B2 (ja) 2024-10-17

Family

ID=77167918

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023504008A Active JP7569443B2 (ja) 2020-07-20 2021-07-20 テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法
JP2024174734A Active JP7795064B2 (ja) 2020-07-20 2024-10-04 テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法
JP2025207454A Pending JP2026035735A (ja) 2020-07-20 2025-11-28 テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024174734A Active JP7795064B2 (ja) 2020-07-20 2024-10-04 テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法
JP2025207454A Pending JP2026035735A (ja) 2020-07-20 2025-11-28 テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法

Country Status (16)

Country Link
US (3) US12037339B2 (cg-RX-API-DMAC7.html)
EP (1) EP4182020A1 (cg-RX-API-DMAC7.html)
JP (3) JP7569443B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260040657A (cg-RX-API-DMAC7.html)
CN (8) CN122516177A (cg-RX-API-DMAC7.html)
AU (2) AU2021311567B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000932A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186217A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000196A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023001407A2 (cg-RX-API-DMAC7.html)
IL (2) IL299704B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000943A (cg-RX-API-DMAC7.html)
PE (1) PE20230854A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550130A1 (cg-RX-API-DMAC7.html)
UA (1) UA130727C2 (cg-RX-API-DMAC7.html)
WO (1) WO2022017338A1 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2022052958A1 (en) * 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US12643905B2 (en) 2021-07-23 2026-06-02 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US20240366639A1 (en) * 2021-08-12 2024-11-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1
CN118791482B (zh) * 2022-11-20 2025-09-09 药康众拓(北京)医药科技有限公司 一种氘代吲唑类化合物、药物组合物及其应用
IL321043A (en) * 2022-12-15 2025-07-01 Sironax Ltd SARM1 modulators, their preparations and uses
IL321472A (en) * 2022-12-19 2025-08-01 Lilly Co Eli Process for the production of GLP1 RA and intermediates therefor
US20260217707A1 (en) * 2023-01-17 2026-07-30 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
CN119630663B (zh) * 2023-06-29 2025-10-21 韦恩生物科技有限公司 一种glp-1受体激动剂及其制备方法和用途
TW202506108A (zh) * 2023-06-30 2025-02-16 大陸商正大天晴藥業集團股份有限公司 含多稠環結構的化合物
WO2025011664A1 (zh) 2023-07-12 2025-01-16 歌礼制药(中国)有限公司 Glp-1r激动剂的制剂及其制备方法
AU2024317579A1 (en) 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025026436A1 (zh) * 2023-08-02 2025-02-06 韦恩生物科技有限公司 一种含氮并环化合物及其制备方法和用途
EP4771001A1 (en) * 2023-08-31 2026-07-08 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025097835A1 (zh) 2023-11-10 2025-05-15 重庆医药工业研究院有限责任公司 一种glp-1r激动剂化合物及其应用
WO2025103443A1 (zh) * 2023-11-16 2025-05-22 海思科医药集团股份有限公司 一种咪唑-2-酮衍生物及其在医药上的应用
KR20260118441A (ko) 2023-11-21 2026-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용
WO2025109387A1 (en) * 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
AU2024394361A1 (en) * 2023-12-05 2026-06-18 Fortvita Biologics Inc. Glp-1 receptor targeting compounds and uses thereof
CN122438847A (zh) * 2023-12-14 2026-07-21 广东众生睿创生物科技有限公司 一种杂环glp-1受体激动剂及其应用
WO2025131043A1 (zh) * 2023-12-22 2025-06-26 石药集团百克(山东)生物制药股份有限公司 一类多环化合物及其用途
CN117447493A (zh) * 2023-12-25 2024-01-26 药康众拓(北京)医药科技有限公司 氘代吲哚嗪类化合物、药物组合物及其应用
CN117777111A (zh) * 2023-12-26 2024-03-29 上海苏博医药科技有限公司 一种Orforglipron关键中间体的合成方法及其中间体
CN122514525A (zh) * 2024-01-10 2026-08-04 海思科医药集团股份有限公司 一种四氢吡啶并吡唑衍生物及其在医药上的应用
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
CN120813584A (zh) * 2024-01-30 2025-10-17 海创药业股份有限公司 一种具有glp-1受体激动剂作用的小分子化合物及其用途
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2025176130A1 (zh) * 2024-02-19 2025-08-28 上海壹迪生物技术有限公司 一种含吡唑并环类化合物、其药物组合物及其用途
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
TW202602880A (zh) * 2024-03-29 2026-01-16 美商拜歐美亞富成股份有限公司 雜環glp-1r促效劑
WO2025209515A1 (zh) * 2024-04-03 2025-10-09 广州市联瑞制药有限公司 一种glp-1受体激动剂及其制备方法和应用
WO2025237355A1 (zh) * 2024-05-17 2025-11-20 成都地奥九泓制药厂 一种glp-1受体激动剂化合物、其制备方法及其应用
WO2025247390A1 (zh) * 2024-05-31 2025-12-04 福佑泰生物制药公司 可用作glp-1r激动剂的杂双环化合物
WO2025259825A1 (en) 2024-06-12 2025-12-18 Eli Lilly And Company Glp-1 npa therapies for maintaining body weight loss or reduced hba1c levels following a prior glp-1 ra treatment
WO2025261454A1 (zh) * 2024-06-19 2025-12-26 上海翰森生物医药科技有限公司 一种含氮大环化合物衍生物调节剂及其制备方法和应用
WO2025264023A1 (en) * 2024-06-19 2025-12-26 Chong Kun Dang Pharmaceutical Corp. Glp-1 receptor agonist, and uses thereof
WO2026001866A1 (zh) * 2024-06-24 2026-01-02 联邦生物科技(珠海横琴)有限公司 一种glp-1受体激动剂及其应用
WO2026007995A1 (zh) * 2024-07-03 2026-01-08 成都地奥九泓制药厂 一种杂环类glp-1受体激动剂化合物、其制备方法及其应用
WO2026012416A1 (zh) * 2024-07-11 2026-01-15 江苏德源药业股份有限公司 杂环类化合物、药物组合物及其应用
WO2026012449A1 (zh) * 2024-07-12 2026-01-15 联邦生物科技(珠海横琴)有限公司 一种具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026031819A1 (en) * 2024-08-06 2026-02-12 Insilico Medicine Ip Limited Novel compounds as glp-1r agonists and uses thereof
WO2026041075A1 (en) * 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
CN119100966B (zh) * 2024-09-02 2025-09-09 上海毕得医药科技股份有限公司 一种溴代吡咯甲酸甲酯的合成方法
WO2026055512A1 (en) * 2024-09-05 2026-03-12 Biomea Fusion, Inc. Combination of a menin inhibitor with a pyrazolopiperidine glp-1 receptor agonist for treating diabetes and obesity
WO2026052129A1 (zh) * 2024-09-09 2026-03-12 中国科学院上海药物研究所 多环杂芳烃类glp-1受体激动剂
WO2026086876A1 (zh) * 2024-10-23 2026-04-30 郑州同源康医药有限公司 作为glp-1r激动剂的化合物
CN119372270A (zh) * 2024-10-25 2025-01-28 成都安迈博生物医药有限公司 一种通过酶催化构建Orforglipron吡喃环手性的方法
WO2026096330A1 (en) * 2024-10-28 2026-05-07 Merck Sharp & Dohme Llc Glp-1 receptor agonists and methods of use
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases
WO2026092580A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases
WO2026092581A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata
WO2026093542A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Glp1r agonist and sglt-2 inhibitor combination therapy
WO2026093539A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Methods of treating or managing obesity
WO2026093541A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Dosage regimens for azd5004
WO2026093537A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Methods of treating diabetes
WO2026093543A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Glp1r agonist and pcsk9 inhibitor combination therapy
CN119101040B (zh) 2024-11-08 2025-03-21 杭州澳赛诺医药技术有限公司 一种通过去对称化合成芳基取代的手性四氢吡喃环的方法
WO2026103930A1 (zh) * 2024-11-18 2026-05-21 西藏海思科制药有限公司 一种咪唑-2-酮衍生物及其在医药上的应用
WO2026130384A1 (zh) * 2024-12-17 2026-06-25 上海翰森生物医药科技有限公司 一种苯并含氮杂环类衍生物、其制备方法和应用
WO2026153543A1 (zh) * 2025-01-20 2026-07-23 歌礼制药(中国)有限公司 Glp-1r激动剂的晶型及其制备方法和用途
WO2026158353A1 (zh) * 2025-01-23 2026-07-30 联邦生物科技(珠海横琴)有限公司 具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026158377A1 (zh) * 2025-01-24 2026-07-30 联邦生物科技(珠海横琴)有限公司 具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026165082A1 (en) * 2025-01-28 2026-08-06 Ambrosia Biosciences Inc. Small molecule glp-1 agonists
CN120309500B (zh) * 2025-06-19 2025-08-15 南昌大学 奥格列龙原料中间体及合成方法与奥格列龙原料合成方法
CN121949295A (zh) * 2026-03-31 2026-05-01 成都安迈博生物医药有限公司 一种构建aleniglipron关键中间体的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014133008A1 (ja) 2013-02-27 2014-09-04 塩野義製薬株式会社 Ampk活性化作用を有するインドールおよびアザインドール誘導体
WO2018056453A1 (ja) 2016-09-26 2018-03-29 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体
WO2019166951A1 (en) 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014133008A1 (ja) 2013-02-27 2014-09-04 塩野義製薬株式会社 Ampk活性化作用を有するインドールおよびアザインドール誘導体
WO2018056453A1 (ja) 2016-09-26 2018-03-29 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体
US20190225604A1 (en) 2016-09-26 2019-07-25 Chugai Seiyaku Kabushiki Kaisha Pyrazolopyridine derivative having glp-1 receptor agonist effect
WO2019166951A1 (en) 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b

Also Published As

Publication number Publication date
JP7795064B2 (ja) 2026-01-07
CA3186217A1 (en) 2022-01-27
JP2023534983A (ja) 2023-08-15
PH12023550130A1 (en) 2024-06-24
US20250059192A1 (en) 2025-02-20
AU2025237942A1 (en) 2025-10-16
US12037339B2 (en) 2024-07-16
AU2021311567B2 (en) 2025-07-10
CN122461300A (zh) 2026-07-28
CN116390926A (zh) 2023-07-04
CN122483082A (zh) 2026-07-31
CN122398793A (zh) 2026-07-17
CO2023001407A2 (es) 2023-02-16
IL299704B1 (en) 2026-07-01
KR20260040657A (ko) 2026-03-25
US11584751B1 (en) 2023-02-21
UA130727C2 (uk) 2026-04-29
EP4182020A1 (en) 2023-05-24
AU2021311567A1 (en) 2023-02-16
CN122516176A (zh) 2026-08-07
JP2026035735A (ja) 2026-03-04
CN122398794A (zh) 2026-07-17
US20230051320A1 (en) 2023-02-16
CL2023000196A1 (es) 2023-09-15
MX2023000943A (es) 2023-02-22
BR112023000932A2 (pt) 2023-10-03
IL328692A (en) 2026-07-01
IL299704A (en) 2023-03-01
KR20230048056A (ko) 2023-04-10
WO2022017338A1 (en) 2022-01-27
CN116390926B (zh) 2026-05-19
CN122516177A (zh) 2026-08-07
CN122351233A (zh) 2026-07-10
JP2025004124A (ja) 2025-01-14
KR102936860B1 (ko) 2026-03-12
PE20230854A1 (es) 2023-05-29

Similar Documents

Publication Publication Date Title
JP7795064B2 (ja) テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法
TWI855062B (zh) Bcl-2抑制劑
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン-2受容体アゴニストとしてのそれらの使用
US20220348564A1 (en) Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same
CN105121426B (zh) 吡咯烷gpr40调节剂
AU2024206693A1 (en) Shp2 inhibitor and uses thereof
CN112566637A (zh) Glp-1受体激动剂及其用途
CN109111451B (zh) 二氢嘧啶类化合物及其在药物中的应用
WO2021078301A1 (zh) 蛋白降解剂及其在疾病治疗中的应用
CN112174935A (zh) 可用作shp2抑制剂的新型杂环衍生物
JP2025528804A (ja) イソインドリン置換グルタルイミド骨格に基づく化合物、及びその応用
CN113072542A (zh) RORγt抑制剂及其制备方法和用途
CN107108625A (zh) 螺环衍生物
JP2019510782A (ja) ブロモドメイン阻害薬としてのピリジル誘導体
CN106458987B (zh) 用于治疗疾病诸如糖尿病的吡咯烷gpr40调节剂
JP7703272B2 (ja) Ssao阻害剤およびその使用
CN113072546A (zh) 五元杂芳衍生物及其制备方法和用途
BR122025022209A2 (pt) Compostos de tetra-hidropirazolo-piridinil-di-hidroimidazolona, composição farmacêutica e seus usos
CN114181205B (zh) 吡唑并吡啶类化合物或其盐及其制备方法和用途
HK40069684A (en) Pyrazolopyridine compounds or salts thereof and their preparation methods and uses
EA049031B1 (ru) Соединения тетрагидропиразоло-пиразинил-дигидроимидазолона или тетрагидропиразоло-пиридинил-дигидроимидазолона и способы их применения
KR20250128310A (ko) Hur 조절 화합물 (elavl1)
WO2024067708A1 (zh) 草酸胺类衍生物、包含其的药物组合物及其医药用途
HK40044822A (en) Glp-1 receptor agonists and uses thereof
CN109721555A (zh) 酰化哌嗪类化合物及其用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230522

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20231208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240719

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241004

R150 Certificate of patent or registration of utility model

Ref document number: 7569443

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150